Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.


Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market

GlobeNewswire October 21, 2021

The Power Play by The Market Herald Announces Interviews with Algernon Pharmaceuticals, NextechAR, UCore Rare Metals, Falcon Gold, and Durango Resources on Latest Company News

Accesswire October 15, 2021

Algernon (CSE:AGN) files meeting request with the MHRA for use of DMT in human stroke study

John Ballem  October 13, 2021

Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study

GlobeNewswire October 13, 2021

Algernon (CSE:AGN) files Pre-IND meeting request for phase 2 Ifenprodil chronic cough study

John Ballem  October 8, 2021

Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study

GlobeNewswire October 8, 2021

Algernon Pharmaceuticals (CSE:AGN) welcomes Dr. Mark Williams to the board

John Ballem  September 22, 2021

Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study

GlobeNewswire September 22, 2021

Algernon Pharmaceuticals Announces the Appointment of Dr. Mark Williams to the Board of Directors

GlobeNewswire September 22, 2021

Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.

GlobeNewswire September 20, 2021

Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company's DMT Program at the International Microdose DMT Conference

GlobeNewswire September 9, 2021

Algernon Pharmaceuticals (CSE:AGN) welcomes Harry Bloomfield, QC. as a board director and chairman

John Ballem  September 9, 2021

Algernon Pharmaceuticals Announces Appointment of Harry Bloomfield, QC. as a New Board Director and Chairman

GlobeNewswire September 9, 2021

Algernon Pharmaceuticals Confirms DMT Increases Neuron Growth

Trevor Abes  September 7, 2021

Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

GlobeNewswire September 7, 2021

Leading DMT Companies to Take Stage at Molecular Masterclass: DMT Conference

Newsfile September 1, 2021

Top 5 Stories of the Week: EV Battery Tech (CSE:ACDC), Bluesky Digital Assets (CSE:BTC), Algernon Pharmaceuticals (CSE:AGN), E79 Resources (CSE:ESNR), and Naturally Splendid (TSXV:NSP)

Trevor Abes  August 13, 2021

Algernon Announces Ifenprodil Research Program & Appoints Dr. William North as Lead Consultant

John Ballem  August 11, 2021

Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant

GlobeNewswire August 11, 2021

Algernon Pharmaceuticals Announces Licensing Agreement with Dartmouth College

John Ballem  August 9, 2021